Clinical Trial Update: Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting results on the effects of dapagliflozin on insulin resistance and insulin secretion in adults with Type 2 Diabetes Mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED | Results posted: 2017-03-01